Item 7.01 Regulation FD Disclosure.
On May 19, 2021, Adaptimmune Therapeutics plc issued a press release announcing
that initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene
autoleucel (afami-cel, formerly ADP-A2M4), will be reported at the American
Society of Clinical Oncology (ASCO) congress. Full abstracts were released
online today, May 19, 2021. Data will be presented in an oral presentation by
Dr. Sandra D'Angelo of the Memorial Sloan Kettering Cancer Center (Abstract
#11504) on June 4, 2021.
The press release is furnished as Exhibit 99.1 and is incorporated by reference
The information in this Item 7.01, including Exhibit 99.1, shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the "Exchange Act") or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description of Exhibit
99.1 Press release dated May 19, 2021
104 Cover Page Interactive Date File (embedded within the Inline XBRL
© Edgar Online, source Glimpses